Decitabine

Highlights in AML and MDS from EHA 2022

Highlights in AML: quizartinib in elderly patients & in frontline FLT3-mutated AML

The current state of the art in HR-MDS and the need to improve treatment approaches

A Phase I/II study evaluating quizartinib plus decitabine and venetoclax in FLT3-mutated AML

Updates from a study evaluating ASTX727 + venetoclax for patients with AML

Maintenance therapy in AML

Lower-intensity frontline therapy for newly diagnosed AML

Unmet needs in high-risk MDS and future therapeutic strategies

10-day decitabine vs 3+7 chemotherapy followed by alloHSCT in older & fit patients with AML

Novel agents of interest for the treatment of BPDCN

Oral combination of HMAs + venetoclax in unfit or elderly patients with AML

Investigating the combination of tolinapant & decitabine in a pre-clinical model for T-cell lymphoma

Emerging treatment strategies for CMML

Diagnosis and management of CMML

Treating MDS patients during the COVID-19 pandemic

Safety and activity of ceralasertib in the treatment of MDS